Efficiency Assessment of the Methodology for the Follow-up of Patients With Knee Prostheses (PROknee)

February 28, 2024 updated by: Antonio Silvestre, University of Valencia

Total knee arthroplasty (TKA) is currently the international standard for the treatment of degenerative and rheumatological diseases of the knee joint, as well as certain types of fractures. Although TKA is a procedure that has been shown to be effective in relieving pain and improving function in patients with osteoarthritis, approximately 20% of patients are dissatisfied with the results. Traditional methods of assessing the outcome after joint arthroplasty often focus on objective indicators of surgery and neglect the needs and opinions of patients. Because of this, this research project has the aim to know the effectiveness of two models of stabilization of total knee prostheses on the functionality achieved and perceived by the patient, as well as in the knee joint biomechanics during movement in activities of daily life. On the other hand, as a secondary objective, we propose to determine prognostic biomarkers of knee prosthesis function based on radiological information, quantification of cytokines, intra-articular markers, and biomechanical functional evaluation that correlate and predict a correct evolution of patients with a knee replacement.

To carry out these objectives, 80 participants will be included with an indication to perform total knee joint replacement surgery. Participants will be randomized allocated into two groups: i. participants with a prosthesis with medial condylar stabilization ii. participants with a traditional prosthesis with central pivot stabilization. Participants will be evaluated at five-times: before surgery, immediate postsurgical, at 3 months of evolution, 6 months of evolution, and one year of evolution.

Study Overview

Detailed Description

I. Objectives

Due to the information reviewed, this research project has the following aims:

  1. To determine the effectiveness of two different prosthesis stabilization procedures of TKA on the functionality achieved and perceived by the patient, as well as on the knee joint biomechanics during movement in activities of daily life.
  2. As a secondary objective, we propose to determine prognostic biomarkers of knee prosthesis function based on radiological information, quantification of cytokines, intra-articular markers, and biomechanical functional evaluation that correlate and predict a correct evolution of patients with knee replacements.

II. General procedures

The study has the approval of the Ethical Committee for Research with Drugs of the University Clinical Hospital of Valencia. Likewise, this study will be conducted at the University Clinical Hospital of Valencia with the INCLIVA Health Research Institute and the University of Valencia (Spain). All assessment procedures will be performed at the Evaluation Unit in Personal Autonomy, Dependence, and Mental Disorders of the Faculty of Medicine at the University of Valencia.

III. Methodology

III.1. Study design

The PROKnee trial was designed as a randomized, controlled, and triple-blinded (patient, raters, and data analysts) with two parallel groups.

III.2 Participants

The inclusion criteria are:

  • People between 50-85 years old and,
  • Primary total knee prosthesis surgery indication with patellar fitting.

The exclusion criteria are as follows:

  • Previous lower limb joint prosthesis,
  • History of fracture or surgery in the lower limb or lumbar spine,
  • Disabling contralateral knee pain,
  • Lower limb length asymmetry > 2 cm,
  • Walking impairment due to other causes non-related to the knee pathology,
  • Body Max Index > 39, and
  • Severe surgical complications such as infection, aseptic loosening, deep vein thrombosis, periprosthetic fracture, and arthrofibrosis.

III.3 Assessment and Outcomes

The study participants will be evaluated in five periods of evolution: before surgery, immediately after surgery, at 3 months of evolution, at 6 months of evolution, and a year after having performed the surgery.

The set of tests to be carried out in each evaluation time and the data to be recorded are the following:

Personal and Anthropometric data:

  • Age (years), Sex (men/women), Gender, BMI (kg/m2), race, level of education, marital status, height, weight, number of chronic diseases besides osteoarthritis, length of inferior extremities measured weight-bearing from the anterior iliac spine (AIS) to the medial malleolus, % of body fat, % of body water.
  • Chronicity of knee symptoms; Diagnosis, Surgical approach, Prosthetic implant, Side of surgery, Days of hospital stay, Leg swelling evaluation with thigh and calf circumference, Hospital readmission, Post-cx complications, Fall Incidence.

Assessment scales:

  • To assess knee and other joint pain it will be used the Visual Analog Scale (EVA).
  • To assess knee function it will be used the Knee Osteoarthritis Outcome Score (KOOS).
  • To assess pain, stiffness, and function it will be used the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).
  • To assess physical activity it will be used the University of California, Los Angeles Physical Activity Questionnaire (UCLA).
  • To assess health-related quality of life it will be used the EuroQol Group 5-dimensions-Level 5 (EQ5D5L) and the Short Form-12 Physical Functioning (SF-12).
  • To assess cognitive state it will be used the Screen for Cognitive Impairment in Psychiatry (SCIP).
  • To assess joint awareness it will be used the Forgotten joint score-12 (FJS-12).
  • To assess anxiety and depression it will be used the Hospital Anxiety and Depression Scale (HADS).

Radiological and Laboratory tests:

  • Imaging tests by radiography on the operated knee
  • Carrying out computed tomography in cases of inadequate function, to identify possible causes, without subjecting the patients to excessive irradiation.
  • Determination of Serum Levels of inflammatory biomarkers status: Interleukin-6, procalcitonin, calprotectin, and C-reactive protein.
  • Determination of intra-joint biomarkers: C-reactive protein, and alpha-defensin.

Biomechanical functional assessment:

  • Range of motion in both knees.
  • Isometric knee strength flexion and extension of the operated and contralateral knee.
  • Lower limb proprioception.
  • Balance assessment during standing position.
  • Kinematic assessment of the lower limb during 1) Six-minute walking test gait, 2) Timed up-and-go test, 3) Gait, 4) Sit to stand Test, 5) Step-over, 6) Stepping up and down stairs.

III.4 Intervention

Participants will be randomized and allocated into two groups: 1) participants with a prosthesis with medial condylar stabilization and, 2) participants with a traditional prosthesis with central pivot stabilization.

III.5 Sample size, recruitment, and randomization

The sample size was estimated based on previous works that compare the medial stabilization knee prosthesis with another device. A small-medium effect (f = 0.15), a statistical significance of 5% at the two-tailed level, and a power of 90% are set, which gives a total of 82 people to be recruited. If 20% of the possible dropouts are considered, the initial recruitment will be of 99 people. Because patient recruitment will occur over a prolonged period, the assignment to the groups will be performed as block randomization with a 1:1 allocation.

Study Type

Interventional

Enrollment (Estimated)

99

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Valencia, Spain, 46010
        • Orthopedic Surgery and Traumatology Service of the University Clinical Hospital of Valencia
      • Valencia, Spain, 46010
        • Unidad de Evaluación en Autonomía Personal, Dependencia y Trastornos Mentales Graves (TMAP), University of Valencia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

48 years to 83 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

The inclusion criteria are:

  • People between 50-85 years old and,
  • Primary total knee prosthesis surgery indication with patellar fitting.

The exclusion criteria are as follows:

  • Previous lower limb joint prosthesis,
  • History of fracture or surgery in the lower limb or lumbar spine,
  • Disabling contralateral knee pain,
  • Lower limb length asymmetry > 2 cm,
  • Walking impairment due to other causes non-related to the knee pathology,
  • Body Max Index > 39, and
  • Severe surgical complications such as infection, aseptic loosening, deep vein thrombosis, periprosthetic fracture, and arthrofibrosis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Total knee prosthesis 1
prosthesis with medial condylar stabilization
Surgery will be done of Total knee prosthesis with medial condylar stabilization
Active Comparator: Total knee prosthesis 2
traditional prosthesis with central pivot stabilization
Surgery will be done of Total knee prosthesis with central pivot stabilization

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum walking speed (MWS)
Time Frame: 1 year
Maximum distance traveled by the body per unit of time (m·s-1). It will ask for participants to walk safely and as quickly as possible, without running, in a 10 m, straight and flat walkway. The two first and last stride will be discarded from the analysis in order to avoid the acceleration and deceleration of the star and end of the gait. The gait speed will be measured with the NedAMH/IBV v5.6 (Institute of Biomechanics of Valencia, Spain) software which uses two infrared or red light photocells to measured gait speed. This outcome will be measured in all the assessment times of the study.
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-reported pain
Time Frame: 1 year
Measured with the Visual Analog Scale (EVA). High scores indicate higher pain sensations.
1 year
Self-reported knee function - Knee Osteoarthritis Outcome Score
Time Frame: 1 year
Measured with the Knee Osteoarthritis Outcome Score (KOOS). It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The score is a percentage score from 0 to 100, 0 representing extreme problems and 100 representing no problems.
1 year
Self-reported knee function - Western Ontario and McMaster Universities Osteoarthritis Index
Time Frame: 1 year
Measured with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). It is consisted of 33 items which evaluates the health and function of the patient from various aspects. The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Higher scores are representative of better situation and less pain.
1 year
Self-reported Physical activity
Time Frame: 1 year
Measured with the University of California, Los Angeles Physical Activity Questionnaire (UCLA). UCLA is a single-item 10-level-scale, ranging from level 10, representing a highly physically active patient, to level 1, a patient who is dependent on others and unable to leave home.
1 year
Joint awareness
Time Frame: 1 year
Measured with the Forgotten joint score-12 (FJS-12) questionnaire; indicates the degree of discomfort that the patient perceives in the activities of daily living produced by the knee pathology. The FJS-12 contains 12 questions which are scored with a Likert scale ranging from 0 to 4. A lower score on the Likert scale equates to less awareness of the joint.
1 year
Health-related quality of life - EuroQol Group 5-dimensions-Level 5
Time Frame: 1 year
Measured with the EuroQol Group 5-dimensions-Level 5 (EQ5D5L). The test covers 5 dimensions of health (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with 5 levels of severity in each dimension (no problems, slight problems, moderate problems, severe problems, and unable to perform or extreme problems). Low scores on each item indicate a good perception of health.
1 year
Health-related quality of life - Short Form-12 Physical Functioning
Time Frame: 1 year
Measured with the Short Form-12 Physical Functioning (SF-12). A higher score indicates higher levels of quality of life.
1 year
Mental status
Time Frame: 1 year
Anxiety and depression will be measured with the Hospital Anxiety and Depression Scale (HADS). HADS is a fourteen-item scale with seven items each for anxiety and depression subscales. Scoring for each item ranges from zero to three. A subscale score >8 denotes anxiety or depression.
1 year
Cognitive status
Time Frame: 1 year
Measured with the Screen for Cognitive Impairment in Psychiatry (SCIP) batery. High scores indicate better cognitive performance.
1 year
Range of motion
Time Frame: 1 year
Active knee range of motion (º) and Passive knee range of motion (º) measured with a manual goniometer.
1 year
Muscle strength
Time Frame: 1 year
Maximum muscle strength during knee flexion (N) and Maximum muscle strength during knee extension (N) registered with an electronic dynamometer.
1 year
Lowe limb proprioception
Time Frame: 1 year
Measured by the number of degrees that the patient makes when equalizing a certain position with their legs. The more degrees of difference, the less proprioception the person being evaluated presents. Will be measured with the Physiological Profile Assessment tool.
1 year
Gait speed during the Six-minute walking test
Time Frame: 1 year
Distance traveled by the body in six minutes (m·s-1).
1 year
Vertical range displacement of the Center of Masses during the Six-minute walking test
Time Frame: 1 year
Range of vertical movement (displacement) performed by the center of mass during the test (mm).
1 year
Medial-lateral range displacement of the Center of Masses during the Six-minute walking test
Time Frame: 1 year
Range of lateral movement (displacement) performed by the center of mass during the test (mm).
1 year
Medial-lateral Jerk during the Six-minute walking test
Time Frame: 1 year
Lateral change rate of acceleration taken by the measured person while performing the test (m/s3)
1 year
Anterior-posterior Jerk during the Six-minute walking test
Time Frame: 1 year
Anterior-posterior change rate of acceleration taken by the measured person while performing the test (m/s3)
1 year
Power Spectral Density in turning during the Six-minute walking test
Time Frame: 1 year
Distribution of movement power over the frequency bands associated with movement during the trial (W/Hz).
1 year
Total execution time of Timed up and go test
Time Frame: 1 year
Time spent by the person evaluated to perform the test (s)
1 year
Vertical range displacement of the Center of Masses during Timed up and go test
Time Frame: 1 year
Range of vertical movement (displacement) performed by the center of mass during the test (mm).
1 year
Medial-lateral range displacement of the Center of Masses during Timed up and go test
Time Frame: 1 year
Range of lateral movement (displacement) performed by the center of mass during the test (mm).
1 year
Medial-lateral Jerk during Timed up and go test
Time Frame: 1 year
Lateral change rate of acceleration taken by the measured person while performing the test (m/s3)
1 year
Anterior-posterior Jerk during Timed up and go test
Time Frame: 1 year
Anterior-posterior change rate of acceleration taken by the measured person while performing the test (m/s3)
1 year
Power Spectral Density in turning during Timed up and go test
Time Frame: 1 year
Distribution of movement power over the frequency bands associated with movement during the trial (W/Hz).
1 year
Gait speed carried out in a 10-meter flat and unobstructed corridor
Time Frame: 1 year
(ms-1)
1 year
Stride length during gait
Time Frame: 1 year
Distance traveled by the person measured from the heel contact of one leg to the next heel contact of the same leg; measured in a 10-meter flat and unobstructed corridor with a 3D photogrammetry system and two dynamometric platforms (m).
1 year
Cadence during gait
Time Frame: 1 year
Number of the steps calculated in a minute, measured in a 10-meter flat and unobstructed corridor with a 3D photogrammetry system and two dynamometric platforms (steps/min).
1 year
Stance time during gait
Time Frame: 1 year
Percentage of the gait cycle that lasts the stance phase measured in a 10-meter flat and unobstructed corridor with a 3D photogrammetry system and two dynamometric platforms (% gait cycle).
1 year
Maximum knee extension during the stance phase of gait
Time Frame: 1 year
Maximum knee extension achieved during the stance phase of gait measured in a 10-meter flat and unobstructed corridor with a 3D photogrammetry system (º).
1 year
Maximum knee flexion during the swing phase of gait
Time Frame: 1 year
Maximum knee flexion achieved during the swing phase of gait measured in a 10-meter flat and unobstructed corridor with a 3D photogrammetry system (º).
1 year
Ground reaction force during weight acceptance of gait cycle
Time Frame: 1 year
First peak of vertical force during stance phase of gait measured in a 10-meter flat and unobstructed corridor with a system of two dynamometric platforms (N).
1 year
Ground reaction force during toe-off of gait cycle
Time Frame: 1 year
Second peak of vertical force during stance phase of gait measured in a 10-meter flat and unobstructed corridor with a system of two dynamometric platforms (N).
1 year
Maximum vertical force during Sit-to-stand test
Time Frame: 1 year
Maximum vertical force of prosthetic leg and no-operated leg, calculated for sitting and standing phases separately; measured with a system of two dynamometric platforms (N).
1 year
Knee momentum during Sit-to-stand test
Time Frame: 1 year
Product of knee mass and speed of movement performed for the prosthetic knee and no-operated knee, calculated for sitting and standing phases separately; measured with a 3D photogrammetry system (Nm).
1 year
Knee range of motion during Sit-to-stand test
Time Frame: 1 year
Range of motion achieved by the prosthetic knee and no-operated knee, calculated for sitting and standing phases separately; measured with a 3D photogrammetry system (º).
1 year
Knee angular velocity during Sit-to-stand test
Time Frame: 1 year
Rate of change of angular position with respect to time of the prosthetic knee and no-operated knee, calculated for sitting and standing phases separately; measured with a 3D photogrammetry system (º/seg).
1 year
Maximum vertical ground reaction force in the single stance of the Step-over test
Time Frame: 1 year
Maximum vertical ground reaction force in the single stance over the step for the prosthetic and no-operated knee, measured with a system of two dynamometric platforms (N)
1 year
Maximum vertical ground reaction force in landing phase of the Step-over test
Time Frame: 1 year
Maximum vertical ground reaction force in landing for the prosthetic and no-operated knee, measured with a system of two dynamometric platforms (N)
1 year
Knee momentum during the single stance phase of the Step-over test
Time Frame: 1 year
Product of knee mass and speed of movement performed during the single stance step for the prosthetic and no-operated knee, measured with a 3D photogrammetry system (Nm)
1 year
Knee range of motion Step-over test
Time Frame: 1 year
Range of motion achieved during the trial for the prosthetic and no-operated knee, measured with a 3D photogrammetry system (º)
1 year
Knee angular velocity during swing phase of the Step-over test
Time Frame: 1 year
Rate of change of angular position with respect to time for the prosthetic and no-operated knee, during the swing phase of step over, measured with a 3D photogrammetry system (º/s)
1 year
Maximum knee flexion from Stepping up and down stairs test
Time Frame: 1 year
Maximum knee flexion during up and down for the prosthetic and no-operated knee and measured with a 3D photogrammetry system (º)
1 year
Knee angular velocity from Stepping up and down stairs test
Time Frame: 1 year
Rate of change of angular position with respect to time during up and down, for the prosthetic and no-operated knee and measured with a 3D photogrammetry system (º/s)
1 year
Maximum vertical ground reaction force in single support from Stepping up and down stairs test
Time Frame: 1 year
Maximum vertical ground reaction force in single support during up and down for the prosthetic and no-operated knee and measured with two dynamometric platforms (N).
1 year
Flexion/extension knee momentum in up and down from Stepping up and down stairs test
Time Frame: 1 year
Product of knee mass and speed of movement performed for the prosthetic and no-operated knee and measured with a 3D photogrammetry system (Nm).
1 year
Varus/valgus knee momentum during up and down from Stepping up and down stairs test
Time Frame: 1 year
Product of knee mass and speed of movement performed for the prosthetic and no-operated knee and measured with a 3D photogrammetry system (Nm).
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Antonio Silvestre Muñoz, PhD., Orthopedic Surgery and Traumatology Service of the University Clinical Hospital of Valencia, Spain.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 27, 2021

Primary Completion (Actual)

July 28, 2023

Study Completion (Estimated)

July 1, 2024

Study Registration Dates

First Submitted

April 8, 2021

First Submitted That Met QC Criteria

April 19, 2021

First Posted (Actual)

April 20, 2021

Study Record Updates

Last Update Posted (Estimated)

March 4, 2024

Last Update Submitted That Met QC Criteria

February 28, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Total Knee Arthroplasty

Clinical Trials on Total knee prosthesis with medial condylar stabilization

3
Subscribe